Highlights from Day 2 of the AAO Congress

Article

New roles for the femtosecond discussed. Subretinal implant disappoints. Genentech defends its actions relating to Avastin decision. Glaucoma pipeline looks very healthy, and much more.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Sunita Radhakrishnan, MD, an associate at the Glaucoma Center of San Francisco, speaks at the annual Glaucoma 360 meeting about electrical neurostimulation.
Related Content
An illustration of a brain beneath a magnifying glass. Concept image for neuroophthalmological exam and ocular symptom paediatric neurology concept. Image credit: ©meeboonstudio – stock.adobe.com

Vision- and life-threatening neuro-ophthalmological presentations

Lorcan Butler, BSc (Hons), MCOptom, Prof Cert Paed Eye Care
April 25th 2025
Article

Paediatric diagnoses of juvenile idiopathic intracranial hypertension, optic neuritis and Horner syndrome

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A young boy with glasses reading a book. Concept image for atropine drop paediatric myopia treatment approval in India. Image credit: ©WESTOCK – stock.adobe.com

ENTOD Pharmaceuticals announces CDSCO approval of 0.05% atropine drops (Myatro XL)

Hattie Hayes;Emily Kaiser Maharjan;Jordana Joy
April 23rd 2025
Article

According to a press release, Myatro XL is the first 0.05% atropine eye drop for paediatric myopia control.

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A photo of a boardroom with a presenter's projector screen, and easel, and many chairs. Concept image for Beth Marsh appointed CCO chief commercial officer of Neurotech Pharmaceuticals, ophthalmic industry news update. Image credit: ©nnpp's Images – canva.com

Neurotech appoints Beth Marsh as chief commercial officer ahead of US product launch

Kassi Filkins
April 22nd 2025
Article

The US FDA recently approved revakinagene taroretcel-lwey (ENCELTO) for the treatment of idiopathic macular telangiectasia type 2 (MacTel)

A series of gears with arrows pointing right in the center of each one. Concept image for five-step approach to dry eye disease. Image credit: ©Cagkan – stock.adobe.com

New trends in the diagnosis of dry eye disease: A patient-centric approach

Marc Labetoulle, MD, PhD
April 21st 2025
Article

A five-step approach to personalise and simplify treatment, leading to higher efficacy

© 2025 MJH Life Sciences

All rights reserved.